Your session is about to expire
← Back to Search
Iohexol-aided Carboplatin Dosing for Cancer
Study Summary
This trial is testing whether iohexol can help doctors calculate the dose of carboplatin given to cancer patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I am male.I am a male interested in joining the study.I've had a recent kidney injury, have sickle cell disease, or currently use nephrostomy tubes.If you have had your whole or part of a limb amputated, you cannot participate because it can affect how a substance called iohexol spreads in your body.I do not have significant fluid buildup in my abdomen or chest.I have been taking my anti-inflammatory or blood pressure medication regularly for the last week.I will be treated with carboplatin through a clinical trial or as standard care.I am mentally and physically able to follow the study's requirements.I will use contraception as required by my treatment plan.I have a thyroid condition but it's not hypothyroidism.You have had an allergic reaction to CT scan dye, iodine, shellfish, or any food item that caused a severe allergic reaction in the past.I have poor vein access for blood draws.
- Group 1: Treatment (iohexol, standard care carboplatin, blood samples)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are involved in the current clinical trial?
"This clinical trial necessitates 250 eligible participants, and recruiting is taking place in two centres - UPCI located in Pittsburgh, Pennsylvania; and Saint Louis Cancer & Breast Institute-Ballwin in Ballwin, New york."
Are there any precedents of research that have utilized Iohexol?
"Iohexol was initially investigated in 2002 at H Central de Asturias. Since then, 866 studies have been completed with 711 currently active experiments, many of which are conducted out of Pittsburgh, Pennsylvania."
What potential hazards do patients face when taking Iohexol?
"Iohexol has been minimally studied, hence it received a score of 1 on our risk assessment scale. This is because this medical trial is in the early stages and lacks sufficient data to ensure safety."
Are there a plentiful number of medical centers conducting this trial in North America?
"This study is being conducted in various locations, including University of Pittsburgh Cancer Institute (UPCI) in Pennsylvania, Saint Louis Cancer and Breast Institute-Ballwin in New york, Memorial Sloan Kettering Cancer Center in Virginia, and a further 100 sites."
Are new participants being enrolled in this research project?
"Clinicaltrials.gov reports that recruitment for this clinical trial is still ongoing, following its initial posting on November 18th 2019 and latest update from August 31st 2022."
What are the main goals of this medical experiment?
"The principal objective of this 4-week clinical trial is to discover the relationship between carboplatin clearance and mGFR. Secondary goals involve measuring the divergence of eGFR from mGFR, ascertaining how accurately target carboplatin AUCs can be reached among patients with elevated eGFR levels, and assessing if pre-treatment serum markers other than creatinine aid in providing an estimate for kidney function for cancer patients."
Share this study with friends
Copy Link
Messenger